Medullary thyroid cancer prevention
Medullary thyroid cancer Microchapters |
Differentiating Medullary thyroid cancer from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Medullary thyroid cancer prevention On the Web |
American Roentgen Ray Society Images of Medullary thyroid cancer prevention |
Risk calculators and risk factors for Medullary thyroid cancer prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
According to the American Society of Clinical Oncology, surveillance for medullary thyroid cancer by annual measurement of serum calcitonin, serum calcium, serum parathyroid hormone, and catacholamines is recommended postsurgically to monitor for recurrence and complications for medullary thyroid cancer.
Secondary Prevention
Surveillance of medullary thyroid cancer | |
---|---|
Serum calcium level annually for people diagnosed with multiple endocrine neoplasia type 2A | |
Recurrent or residual medullary thyroid cancer post thyroidectomy is detected by measurement of serum calcitonin annually | |
Catacholamines, epinephrine and norepinephrine yearly for multiple endocrine neoplasia type 2A and multiple endocrine neoplasia type 2B patients to detect pheochromocytoma | |
Magnetic resonance imaging and computerized tomography for pheochromocytoma every 2-4 years | |
Parathyroid hormone level yearly for multiple endocrine neoplasia type 2A to detect hypoparathyroidism | |
Adapted from Marquard J, Eng C. Multiple Endocrine Neoplasia Type 2. 1999 Sep 27 [Updated 2015 Jun 25]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1257/[1] |
References
- ↑ Jessica Marquard & Charis Eng (1993). "Multiple Endocrine Neoplasia Type 2". PMID 020301434.